BioCentury
ARTICLE | Clinical News

Chimerix preclinical data

October 13, 2014 7:00 AM UTC

Chimerix said in vitro data from studies conducted at the CDC and NIH showed that brincidofovir has activity against Ebola that is "similar" to that seen with brincidofovir against adenovirus and smallpox. The CDC and NIH are conducting additional studies of brincidofovir in animal models of Ebola.

Chimerix also said FDA approved its emergency IND allowing the company to provide brincidofovir to treat Ebola. The company said it is working with FDA to finalize a clinical trial protocol of brincidofovir to treat Ebola. On Oct. 4, Texas Health Presbyterian Hospital began treating an Ebola patient with brincidofovir. The patient, who was the first known person with Ebola in the U.S., passed away on Oct. 8. ...